IVF Success Rates Can Overpromise: The Denominator Problem, Embryo Math, and Pelvic Pathology

By Andrea Vidali, MD

Reproductive Surgeon & Reproductive Immunologist · ESSI

internationalendo.com | ESSI Science Commentary

Patients deep in the fertility system are routinely handed single-cycle statistics. They are told about per-transfer percentages and hopeful cumulative probabilities, leaving them to view IVF as an endless assembly line of retrievals and transfers.

This commentary argues for a fundamental paradigm shift: fertility care should not be sold as a generalized statistic. Patients require comprehensive start-to-baby counseling that explicitly details how many retrievals, how many embryos, how much time, and how much financial and emotional capital will be consumed—and whether underlying endometriosis, adenomyosis, or recurrent pregnancy loss must be treated before precious embryos are spent.

A recent, landmark commentary in Reproductive BioMedicine Online (RBMO) highlights this structural gap, arguing that IVF should be counseled not as a single isolated cycle, but as a comprehensive course of treatment. The authors propose a new prognostic tool: the Expected Live Birth Rate (ELBR). The ELBR serves as a complete estimate of how many total eggs, blastocysts, retrievals, and transfers a specific couple will require to achieve a realistic probability of a live birth.

This is a necessary and transparent shift in reproductive medicine. Patients deserve more than an abstract per-transfer number. They need a realistic look at the entire biological pathway: the retrievals, the attrition from oocyte to blastocyst, the euploid conversion rates, the cumulative cost, the ticking clock of age, and the very real possibility of stopping treatment before a quoted cumulative success rate is ever reached.

Because underneath the default optimism of modern fertility marketing, IVF has a structural tendency to overpromise.

This does not always happen intentionally or maliciously. It happens structurally. IVF presents success in a way that sounds highly achievable to the general population, but frequently misrepresents the biological reality of the individual patient sitting in the consultation room.

The primary reason for this disconnect is simple: most optimistic IVF statistics assume that patients have an unlimited abundance of embryos to keep trying. In the real world, many patients do not.

The Illusion of Cumulative Rates: The Denominator Problem

One of the most reassuring concepts in modern reproductive endocrinology is that if a patient continues transferring genetically normal (euploid) embryos, the cumulative probability of a live birth eventually approaches nearly 100%. Biologically, this makes sense. If you transfer enough chromosomally normal embryos into a receptive environment, a majority of patients will eventually succeed.

The problem is that this statistical truth is heard by patients as a guarantee, even when that individual patient may never possess enough embryo currency to test the promise.

The RBMO commentary analyzes a massive dataset by Gill et al. tracking 123,987 patients. In this dataset, the cumulative live-birth rate after up to five consecutive euploid blastocyst transfers reached an extraordinary 98%.

On a marketing brochure, that 98% number sounds definitive. But a closer look at the actual clinical funnel reveals a glaring diagnostic blind spot: only 105 patients out of the original 123,987 had more than three euploid blastocysts available in the relevant post-failure group. In the final data synthesis, an even smaller fraction of patients ever actually reached a fifth euploid transfer.

This is the definition of The Denominator Problem. The numerator looks spectacular, but the denominator is microscopic.

[

Figure 1 — An analytical funnel infographic titled “IVF Can Overpromise: The Denominator Problem” charting the steep decline from 123,987 database patients down to 105 patients with >3 euploids, to 45 patients reaching a 5th transfer, culminating in the 98% statistic to illustrate how tiny the final population baseline truly is. 

The relevant clinical question is not: What happens if a patient transfers five normal embryos?

The true clinical question is: What proportion of patients starting an IVF cycle can actually produce five normal embryos within a reasonable number of retrievals, at a tolerable cost, before they run out of time, financial resources, ovarian reserve, or emotional stamina?

Those are two completely different biological questions.

A success statistic is only useful if the patient actually belongs to the population from which that statistic was derived. A young, 28-year-old patient with an abundant ovarian reserve and a high blastocyst yield does not belong to the same clinical population as a 39-year-old patient with Stage IV deep infiltrating endometriosis, adenomyosis, low AMH, a single precious euploid embryo, and a history of recurrent pregnancy loss. Yet, too often, they are counseled using the exact same general IVF optimism.

This is where reproductive medicine must shift its focus from generalized cycle success to individualized patient success.

Figure 2 — A workflow infographic titled “From Cycle Success to Patient Success” mapping out the points of attrition from Treatment Start ➡️ Oocyte Retrieval ➡️ Blastocyst Creation ➡️ Euploid Screening ➡️ Embryo Transfer ➡️ Live Birth, highlighting a 36% fertility-treatment drop-out rate across 330,593 patients.

Embryo Math: Currency Is Not Unlimited

At ESSI, we approach reproductive strategy through the lens of a finite embryo economy. Embryos are not an infinite currency; they represent a strictly limited inventory.

For a high-reserve patient, repeating transfers without deep diagnostic investigation may be a statistically viable option. But for patients over 35, or those navigating advanced endometriosis, ovarian endometriomas, prior pelvic surgeries, and low AMH, embryos are a scarce and precious resource.

In a closed embryo economy, every single transfer matters. Every failed implantation, every miscarriage, and every directional delay carries an immense biological and emotional tax.

The data adapted from the RBMO framework makes this math starkly visible. As maternal age increases and baseline ovarian reserve falls, the number of oocyte retrievals required to generate a viable embryo inventory rises exponentially.

Figure 3 — A clinical data table titled “Embryo Math Matters” cross-referencing Maternal Age (<35, 35-37, 38-40, >40) with Ovarian Reserve (High, Normal, Low) to display the required number of blastocysts, eggs, and total estimated oocyte retrievals needed to achieve success. 

This matrix proves why quoting general cumulative live-birth rates can be profoundly misleading if a patient’s individual embryo creation capacity is not evaluated first. Low ovarian reserve can quickly escalate a treatment plan from a single routine cycle into a requirement for 4 to 10 retrievals—a threshold where a massive percentage of patients drop out due to emotional and financial exhaustion.

Endometriosis and Adenomyosis Alter the Equation

Endometriosis is routinely misunderstood by the general medical community. It is often treated as a localized disease of “bad periods,” or patients are told that IVF can easily bypass it. This is an incomplete and unscientific view.

IVF is highly effective at bypassing blocked or damaged fallopian tubes. It cannot automatically bypass an inflamed pelvis. It cannot bypass:

• Systemic progesterone resistance

• Chronic retroperitoneal and endometrial inflammation

• Anatomical distortions and dense pelvic adhesions

• Toxic fluid accumulation from a hydrosalpinx

• The immunologic and structural damage of uterine adenomyosis

Furthermore, IVF cannot alter the reality that endometriosis patients frequently have far fewer embryos to work with from the start. Ovarian endometriomas and the scar tissue from previous unspecialized cystectomies deplete healthy follicles, altering the embryo economy early.

Figure 4 — A clinical roadmap infographic titled “Why Endometriosis and RPL Change the IVF Equation” breaking down four strategic quadrants: 1. Finite Embryo Economy, 2. Endometriosis & Adenomyosis environmental penalties, 3. Recurrent Pregnancy Loss systemic factors, and 4. A Smarter Strategy focused on optimization before transfer. 

A patient with unexplained infertility and five banked euploid embryos has a entirely different strategic map than an endometriosis patient with a single euploid embryo and a hostile uterine environment. When embryos are abundant, repeated transfer may be a reasonable data-gathering strategy. When embryos are scarce, uterine and pelvic environmental optimization must take priority.

Recurrent Pregnancy Loss: Looking Beyond Embryo Quality

In the management of recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL), advising a patient to “just try again” without a deep diagnostic workup can be a dangerous strategy.

After a single failed transfer of an untested embryo, it is clinically reasonable to suspect random chromosomal variance or chance. But after repeated failures—especially when utilizing high-quality, genetically tested euploid embryos—the clinical conversation must pivot.

The diagnostic question can no longer be: Was the embryo normal?

The overriding question becomes: Why did a genetically normal embryo fail to implant, or why did a documented pregnancy fail to continue?

This is the exact junction where hidden pelvic pathology—such as deep infiltrating endometriosis, diffuse adenomyosis, chronic endometritis, uterine septums, localized immune dysfunction, and hypercoagulability—becomes hyper-relevant.

If a pregnancy loss is driven entirely by aneuploidy, PGT-A screening protects the patient by filtering out that abnormal embryo. But if losses continue to recur with euploid embryos, or if the statistical probability of repeated aneuploidy drops, the embryo is no longer the bottleneck. The environment matters.

The ESSI Standard: A Transparent Framework for Patient Success

An honest and scientifically sound fertility consultation must separate your journey into three distinct probabilities:

1. The probability of successfully retrieving viable oocytes.

2. The probability of converting those oocytes into usable blastocysts and euploid embryos.

3. The probability that those specific embryos will successfully implant and progress to a live birth inside a unique uterus and pelvis.

Standard IVF counseling focuses almost entirely on the third number, assuming the first two are guaranteed. But your egg yield and embryo math determine whether that optimistic cumulative success rate is even structurally reachable.

Our Position on Integrated Care

This framework is not an argument against the power of IVF. It is an explicit argument against clinical oversimplification. IVF is an extraordinary reproductive tool, but it should never be used as a shield to avoid a clear, root-cause diagnosis.

A failed IVF cycle should not automatically be answered with another identical IVF cycle. A failed euploid transfer should not be met with a default replication of the exact same transfer protocol. A miscarriage should never be dismissed as “bad luck” when a patient has a documented history of pelvic pain or when the embryo is known to be chromosomally perfect.

True clinical progress means recognizing when IVF alone is not enough. For an advanced endometriosis patient, the most intelligent path to a live birth may require meticulous laparoscopic excision surgery (LAPEX) before entering an IVF cycle. For a patient with severe adenomyosis, it requires deep uterine down-regulation or structural optimization before an embryo is spent.

The real paradigm shift in reproductive medicine is not telling patients to blindly commit to more cycles. The real paradigm shift is telling patients the biological truth about their anatomy.

TALK TO THE ESSI REPRODUCTIVE STRATEGY TEAM

If you have hit a wall with repeated failed transfers, have experienced unexplained miscarriages, or want an honest evaluation of your embryo economy before spending your precious resources, our world-class multidisciplinary team is here to design a definitive care map.

References & Literature Register

1. Gianaroli L, Mocanu E, Fatemi H, Sgargi S, Ata B, Fauser BCJM. Helping patients achieve their expected live birth rate: an ART paradigm shift. Reproductive BioMedicine Online. 2026;53(3):105785. doi:10.1016/j.rbmo.2026.105785.

2. Gill P, Ata B, Arnanz A, Cimadomo D, Vaiarelli A, Fatemi HM, Ubaldi FM, Garcia-Velasco JA, Seli E. Does recurrent implantation failure exist? Prevalence and outcomes of five consecutive euploid blastocyst transfers in 123,987 patients. Human Reproduction. 2024;39(5):974-980. doi:10.1093/humrep/deae040.

3. Shen Q, He T, Wang B, Qu J, Peng E, Lei J. Worldwide prevalence of discontinuation in fertility treatment: a systematic review and meta-analysis. International Journal of Gynaecology and Obstetrics. 2026;172(2):772-785. doi:10.1002/ijgo.70440.

4. Dhaenens L, Colman R, De Croo I, Verstraelen H, De Sutter P, Stoop D. Cumulative live birth rates of 31,478 untested embryos from 11,463 women challenge traditional recurrent implantation failure definitions. Human Reproduction. 2025;40(5):818-833. doi:10.1093/humrep/deaf036.

5. Seli E, Kalafat E, Reig A, Whitehead C, Ata B, Garcia-Velasco J. Forecasting Outcomes of Assisted Reproductive Treatments Using Artificial Networks (FORTUNE) classification system: a new prognostic model to predict euploid blastocyst yield in patients undergoing IVF. Human Reproduction. 2025;40(11):2115-2125. doi:10.1093/humrep/deaf163.

METHODOLOGY & SAFETY NOTE: This scientific commentary reflects the strategic and editorial position of the ESSI clinical team based on the cited multi-center registry data and peer-reviewed literature. Expected Live Birth Rates (ELBR) and attrition funnel projections are population-level estimates and do not guarantee individual clinical outcomes. Patients should undergo a comprehensive, personalized diagnostic evaluation with a qualified reproductive specialist to establish an accurate assessment of their ovarian reserve, uterine receptivity, and pelvic disease profile before initiating treatment.